Exelixis Inc. has announced the initiation of a Phase 1 clinical study for XB628, a groundbreaking bispecific antibody designed to treat participants with recurrent advanced or metastatic solid tumors. This first-in-human study marks a significant milestone in the collaboration between Exelixis and Invenra Inc., which was instrumental in discovering this innovative molecule. XB628 functions as a natural killer (NK) cell engager, targeting the inhibitory receptor NKG2A on NK cells and the programmed cell death-ligand 1 (PD-L1). The study aims to evaluate the safety and dosage levels of XB628, potentially offering a new therapeutic option for patients with challenging cancer types.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exelixis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250513934175) on May 13, 2025, and is solely responsible for the information contained therein.